Inflammatory bowel disease - Do microorganisms play a role?;Inflammatorisk tarmsygdom - Spiller mikroorganismer en rolle?

Ugeskrift for Laeger

Volumn 164, Issue 50, 2002, Pages 5947-5950

  Nielsen, Sara Elsøe ^a   Haagen Nielsen, Ole ^a   Vainer, Ben ^a   Claesson, Mogens H ^a  

^a Medicinsk Afdeling   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; CLINICAL ARTICLE; CROHN DISEASE; ENTERITIS; EPSTEIN BARR VIRUS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INTESTINE FLORA; LISTERIA MONOCYTOGENES; MEASLES VIRUS; MUMPS VIRUS; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; INTESTINAL MUCOSA; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; MEASLES; MUMPS; MYCOBACTERIUM PARATUBERCULOSIS; PARATUBERCULOSIS;

EID: 0037049447     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247-56.
2. Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: A sixfold increase in incidence. Scand J Gastroenterol 1992; 27: 609-14.
3. Hubbard J, Surawicz CM. Etiological role of mycobacterium in Crohn's disease: An assessment of the literature. Dig Dis 1999; 17: 6-13.
4. Chamberlin W, Graham DY, Hulten K, el Zimaity HM, Schwartz MR, Naser S et al. Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. Aliment Pharmacol Ther 2001; 15: 337-46.
5. Spahr U, Schafroth K. Fate of Mycobacterium avium subsp. paratuberculosis in Swiss hard and semihard cheese manufactured from raw milk. Appl Environ Microbiol 2001;67:4199-205.
6. Thayer WR Jr, Coutu JA, Chiodini RJ, van Kruiningen HJ, Merkal RS. Possible role of mycobacteria in inflammatory bowel disease. II. Mycobacterial antibodies in Crohn's disease. Dig Dis Sci 1984;29:1080-5.
7. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-8.
8. Thomas GA, Swift GL, Green JT, Newcombe RG, Braniff-Mathews C, Rhodes J et al. Controlled trial of antituberculous chemotherapy in Crohn's disease: A five year follow up study. Gut 1998; 42: 497-500.
9. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Dig Dis Sci 1991; 36: 449-53.
10. Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25: 203-5.
11. Robertson DJ, Sandler RS. Measles virus and Crohn's disease: A critical appraisal of the current literature. Inflamm Bowel Dis 2001; 7: 51-7.
12. Iizuka M, Chiba M, Yukawa M, Nakagomi T, Fukushima T, Watanabe S et al. Immunohistochemical analysis of the distribution of measles related antigen in the intestinal mucosa in inflammatory bowel disease. Gut 2000; 46:163-9.
13. Balzola FA, Castellino F, Colombatto P, Manzini P, Astegiano M, Verme G et al. IgM antibody against measles virus in patients with inflammatory bowel disease: A marker of virus-related disease? Eur J Gastroenterol Hepatol 1997; 9: 661-3.
14. Fisher NC, Yee L, Nightingale P, McEwan R, Gibson JA. Measles virus serology in Crohn's disease. Gut 1997; 41: 66-9.
15. Touze I, Dubucquoi S, Cortot A, van Kruiningen HJ, Colombel JF. IgM-specific measles-virus antibody in families with a high frequency of Crohn's disease. Lancet 1995; 346: 967.
16. Van Kruiningen HJ, Mayo DR, Vanopdenbosch E, Gower-Rousseau C, Cortot A, Colombel JF. Virus serology in familial Crohn's disease. Scand J Gastroenterol 2000; 35: 403-7.
17. Iizuka M, Saito H, Yukawa M, Itou H, Shirasaka T, Chiba M et al. No evidence of persistent mumps virus infection in inflammatory bowel disease. Gut 2001; 48: 637-41.
18. Bertalot G, Villanacci V, Gramegna M, Orvieto E, Negrini R, Saleri A et al. Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig Liver Dis 2001; 33: 551-8.
19. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol 2001; 36 (suppl 234): 29-40.
20. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001; 48: 132-5.
21. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomised, placebo controlled trial. Gut 1997; 40: 485-91.
22. Vernia P, Marcheggiano A, Caprilli R, Fried G, Corrao G, Valpiani D et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 309-13.
23. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: Biological and clinical significance. J Endotoxin Res 2000; 6: 205-14.
24. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997; 150: 91-7.
25. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-31.
26. Contractor NV, Bassiri H, Reya T, Park AY, Baumgart DC, Wasik MA et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998; 160: 385-94.
27. Claesson MH, Bregenholt S, Bonhagen K, Thoma S, Moller P, Grusby MJ et al. Colitis-inducing potency of CD4+ T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12, responsiveness, and CD45RB surface phenotype. J Immunol 1999; 162: 3702-10.
28. Brandwein SL, McCabe RP, Cong Y, Waites KB, Ridwan BU, Dean PA et al. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol 1997; 159: 44-52.
29. Brimnes J, Reimann J, Nissen M, Claesson M. Enteric bacterial antigens activate CD4(+) T cells from scid mice with inflammatory bowel disease. Eur J Immunol 2001; 31: 23-31.
30. Bregenholt S, Claesson MH. Increased intracellular Th1 cytokines in scid mice with inflammatory bowel disease. Eur J Immunol 1998; 28: 379-89.
31. Singh B, Read S, Asseman C, Malmstrom V, Mottet C, Stephens LA et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001; 182: 190-200.
32. Dunne C, Murphy L, Flynn S, O'Mahony L, O'Halloran S, Feeney M et al. Probiotics: From myth to reality. Antonie Van Leeuwenhoek 1999; 76: 279-92.
33. Dunne C. Adaptation of bacteria to the intestinal niche: Probiotics and gut disorder. Inflamm Bowel Dis 2001; 7: 136-45.
34. Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: The importance of the pediatric perspective. Inflamm Bowel Dis 2002; 8: 112-28.